Eli Lilly Gets AIA Reviews Of Institute's Fibrosis Patent
The U.S. Patent and Trademark Office's patent trial board on Thursday granted Eli Lilly Co.'s requests for inter partes reviews of a fibrosis treatment patent owned by a California-based research institute,...To view the full article, register now.
Already a subscriber? Click here to view full article